The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH CML/MPN 2025 | Patient groups representing a significant unmet need in myelofibrosis management
In this video, Michael Loschi, MD, PhD, University Hospital of Nice, Nice, France, briefly outlines the two groups that represent a significant unmet need in myelofibrosis (MF): thrombocytopenic patients and those with accelerated or blast phase disease. Current treatments often yield limited results in these patient groups, and novel therapeutic approaches are needed to improve clinical outcomes. This interview took place at the European School of Haematology (ESH) 4th How to Diagnose and Treat: CML/MPN meeting in Vienna, Austria.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So, so far, I think there were, there remain two big unmet needs. The first one being the thrombocytopenic or highly thrombocytopenic patients. These patients are excluded from the trials, from the combination trials. And this remains a huge unmet need because we don’t have many options to treat these patients actually. Highly thrombocytopenic patients or very severe patients, thrombocytopenia is a negative prognostic factor for survival for this patient and we hope that one day we’ll have a combination for this patient...
So, so far, I think there were, there remain two big unmet needs. The first one being the thrombocytopenic or highly thrombocytopenic patients. These patients are excluded from the trials, from the combination trials. And this remains a huge unmet need because we don’t have many options to treat these patients actually. Highly thrombocytopenic patients or very severe patients, thrombocytopenia is a negative prognostic factor for survival for this patient and we hope that one day we’ll have a combination for this patient.
The other unmet need is for accelerated or blastic phase myelofibrosis patients and for this patient too, we hope that we could do better than what we are doing right now and have better results, maybe by adding one of these new drugs to the drugs we’re already using for these patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Honoraria: Stemline.
